Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides (Q33916110)

30 July 2017

1 reference

title

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides (English)

1 reference

30 July 2017

S Agrawal

1

1 reference

PubMed ID

10806997

30 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

Biochimica et Biophysica Acta

30 July 2017

1 reference

30 July 2017

1489

1 reference

30 July 2017

1

1 reference

30 July 2017

53-68

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

History of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense oligonucleotides: towards clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

In vivo studies with antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense oligonucleotides: is the glass half full or half empty?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Synthesis and anti-HIV activity of oligoribonucleotides and their phosphorothioate analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Immune activation by bacterial DNA: a new genetic code

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pharmacokinetics of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Capped oligodeoxynucleotide phosphorothioates. Pharmacokinetics and stability in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Modified oligonucleotides as therapeutic and diagnostic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Novel enzymatic and immunological responses to oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Effects of synthetic oligonucleotides on human complement and coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Solid-phase stereoselective synthesis of 2'-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Antisense oligonucleotides as antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4781%2899%2900141-4

7 January 2021

10.1016/S0167-4781(99)00141-4

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10806997